Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Valentina Gerussi, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gydé, F. Morel, Corentin Poignon, et al. (15 authors)
Emerging infectious diseases · 2025-02
Abstract
High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.
MeSH terms
- Isoniazid
- Tuberculosis
- Multiple drug resistance
- Medicine
- Extensively drug-resistant tuberculosis
- Mycobacterium tuberculosis
- Virology
- Drug resistance
- Microbiology